Ginkgo Bioworks Holdings (DNA) Operating Income (2020 - 2025)
Ginkgo Bioworks Holdings filings provide 6 years of Operating Income readings, the most recent being -$70.8 million for Q4 2025.
- On a quarterly basis, Operating Income rose 31.71% to -$70.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$315.3 million, a 43.68% increase, with the full-year FY2025 number at -$315.3 million, up 43.68% from a year prior.
- Operating Income hit -$70.8 million in Q4 2025 for Ginkgo Bioworks Holdings, up from -$90.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$26.7 million in Q3 2021 to a low of -$1.7 billion in Q4 2021.
- Median Operating Income over the past 5 years was -$178.1 million (2023), compared with a mean of -$288.8 million.
- Biggest five-year swings in Operating Income: tumbled 2914.48% in 2021 and later surged 86.3% in 2022.
- Ginkgo Bioworks Holdings' Operating Income stood at -$1.7 billion in 2021, then surged by 86.3% to -$230.9 million in 2022, then grew by 22.85% to -$178.1 million in 2023, then surged by 41.83% to -$103.6 million in 2024, then surged by 31.71% to -$70.8 million in 2025.
- The last three reported values for Operating Income were -$70.8 million (Q4 2025), -$90.0 million (Q3 2025), and -$65.5 million (Q2 2025) per Business Quant data.